How could Johnson & Johnson's mixed sales performance affect Genmab?
Genmab may benefit from strong sales of Johnson & Johnson's Darzalex The strong performance of Darzalex, a cancer medicine, drives increased royalty revenue for Genmab. Darzalex posted sales of $4.2 billion, representing a 15.4% increase compared to the year-ago period. Genmab receives royalty revenue from Johnson & Johnson's commercialization of daratumumab, which is the active ingredient in Darzalex, under an exclusive license agreement. Therefore, the robust sales figures reported for Darzalex directly support higher royalty payments flowing to Genmab.
- Effect
- Strong positive
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- No new developments lately
How it reaches Genmab
-
Johnson & Johnson reported third-quarter revenue of $25.4 billion, which was 5.9% higher than the previous year. The innovative medicine segment generated $16.8 billion, up 7.7% year over year. While Darzalex sales increased 15.4% and Tremfya sales increased 68.3%, other key medicines faced declining sales due to competition.
The full event1independent outlet -
Genmab receives royalty revenue from Johnson & Johnson's commercialization of daratumumab under an exclusive license agreement. The higher sales volume and revenue generated by Darzalex directly increases the financial basis for these royalty payments to Genmab.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
Danish healthcare company
Everything about Genmab
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
Why it matters
For Genmab, the royalty revenue stream from Johnson & Johnson is a critical component of its financial stability and growth. The strength of Darzalex sales indicates that one of Genmab's key commercialization partnerships is performing exceptionally well, providing a strong, predictable financial boost.
This performance occurs against a backdrop of mixed results for Johnson & Johnson, where other key drugs like Imbruvica and Remicade are facing competition. The strong showing of Darzalex and Tremfya helps offset these declines, demonstrating that J&J's innovative medicine segment has powerful growth drivers that benefit its partners.
What we don't know yet
- Will the strong sales trend for Darzalex continue into the next fiscal year?
- Are there any changes to the royalty agreement terms that could affect Genmab's revenue?
What would change this answer
— Other considerations
Beyond this explainer
Explore connected ideas
Each opens in Related concepts: what the web connects to it, with Brind's news on it.
The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.
Who else could feel it
Other possible ripples from the same event.
Reporting
- fool.comSaturday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.